Clinical Trial Detail

NCT ID NCT04069026
Title A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

Advanced Solid Tumor

head and neck squamous cell carcinoma

lung non-small cell carcinoma

colorectal cancer

Therapies

BAY2416964

Age Groups: adult senior

No variant requirements are available.